Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in AI-first business consulting and technology services, ...

Visceral fat damages vital organs and drives chronic disease. Learn the best evidence-based ways to reduce it, backed by ...

When Chinese pharmaceutical companies raise the pay of their top executives, the firms themselves tend to perform measurably ...

Value-focused retail formats are growing, while premium categories experience challenges due to stock availability issues.

Tempus AI sits at the intersection of AI infra and clinical diagnostics. It's a holding in both the ROBO Global Artificial ...

A systematic review of 89 studies identifies 53 microRNAs regulating neuroblastoma cell differentiation, with miR-124, miR-34 ...

ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor ...

COCOON shows lazertinib lead-in plus simplified prophylaxis reduced grade ≥2 skin toxicity to 18% with SC amivantamab in EGFR ...

Get latest articles and stories on Business at LatestLY. Bengaluru (Karnataka) [India], October 23: Infosys (NSE: INFY) (BSE: ...

DLL3 PET provides a non-invasive, whole-body assessment of neuroendocrine differentiation and spatial tumor heterogeneity in ...

TROPION-Breast02 shows Dato-DXd improved CNS PFS to 9.5 vs 2.6 months and achieved 62.5% intracranial ORR in TNBC brain ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...